Prognostic Signatures in Breast Cancer

Prognostic signatures are also known as Gene Expression Profiles (GEP) are now commonly used in the clinic to stratify hormone positive breast cancer patients risk of distant recurrence at 10 years and aid treatment strategy decision making. In this blog post, I will review the commonly used GEP and hopefully illustrate their proper clinical utilization as well as limitations. In a previous post, I discussed the adjuvant endocrine therapy for hormone positive breast cancer, for details please click here.

The use of GEP in Early stage breast cancer signficantly reduced the use of Chemotherapy in this patient population.

Continue reading “Prognostic Signatures in Breast Cancer”

Another PARP inhibitor showing promise

PARP inhibitors are unique molecules targeting only the PARP enzyme in BRCA 1/2 mutated cells, they are generally well tolerated as compared to chemotherapy. In this year at San Antonio Breast Cancer Symposium, the EMBRACA trial results were presented in abstract form.

The talazoparib arm patients reported better quality of life score as well as there was a significant delay in the time to deterioration

 

Continue reading “Another PARP inhibitor showing promise”